Nuvation Bio

Yahoo Finance • yesterday

Nuvation Bio Inc. (NUVB): A Bull Case Theory

We came across a bullish thesis on Nuvation Bio Inc. on wallstreetbets subreddit by asagi_lumina. In this article, we will summarize the bulls’ thesis on NUVB. Nuvation Bio Inc.'s share was trading at $3.2200 as of September 23rd.AbCellera... Full story

Yahoo Finance • 2 days ago

Rapid Micro Biosystems And 2 Promising Penny Stocks To Watch

As the U.S. stock market continues to climb, with indices like the Nasdaq and S&P 500 reaching new highs, investors are exploring various opportunities in different segments of the market. Penny stocks, a term that may seem outdated yet re... Full story

Yahoo Finance • 2 months ago

Nuvation Bio Inc (NYSE:NUVB) Reports Mixed Q2 2025 Results with Strong Revenue Beat but Cautious Market Reaction

Nuvation Bio Inc (NYSE:NUVB [https://www.chartmill.com/stock/quote/NUVB]) reported its second-quarter 2025 financial results, delivering mixed performance relative to analyst expectations. The oncology-focused biopharmaceutical company pos... Full story

Yahoo Finance • 3 months ago

Nuvation Bio's SWOT analysis: IBTROZI approval boosts stock prospects

Nuvation Bio Inc. (NYSE:NUVB) has recently transitioned from a clinical-stage to a commercial-stage biotechnology company with the FDA approval of its flagship drug IBTROZI (taletrectinib) for the treatment of ROS1-positive non-small cell... Full story

Yahoo Finance • 4 months ago

Nuvation Bio price target lowered to $6 from $10 at RBC Capital

RBC Capital lowered its price target on Nuvation Bio stock (NYSE:NUVB) to $6.00 from $10.00 on Tuesday, while maintaining an Outperform rating following the company’s recent transformation into a commercial-stage biotech. The stock, curren... Full story

Yahoo Finance • 4 months ago

Nuvation Bio's SWOT analysis: FDA approval boosts stock prospects

Nuvation Bio Inc. (NYSE:NUVB) has recently achieved a significant milestone with the FDA approval of its flagship drug IBTROZI (taletrectinib) for the treatment of ROS1-positive non-small cell lung cancer (NSCLC). This approval marks Nuvat... Full story

Yahoo Finance • 4 months ago

Nuvation Bio granted FDA approval for lung cancer therapy Ibtrozi

[FDA Headquarters - White Oak Campus] hapabapa Nuvation Bio (NYSE:NUVB [https://seekingalpha.com/symbol/NUVB]) announced on Wednesday that the U.S. Food and Drug Administration (FDA) has approved its oral antitumor agent Ibtrozi as a trea... Full story

Yahoo Finance • 6 months ago

Is Nuvation Bio Inc. (NYSE:NUVB) the Best Biotech Penny Stock to Buy According to Hedge Funds?

We recently published a list of the 13 Best Biotech Penny Stocks to Buy According to Hedge Funds. In this article, we are going to take a look at where Nuvation Bio Inc. (NYSE:NUVB) stands against other biotech penny stocks. Peter Marks’s... Full story

Yahoo Finance • 6 months ago

Is Nuvation Bio Inc. (NUVB) the Top Healthcare Stock to Buy According to Billionaire David Einhorn?

We recently published a list of Top 9 Healthcare Stocks to Buy According to Billionaire David Einhorn. In this article, we are going to take a look at where Nuvation Bio Inc. (NYSE:NUVB) stands against other top healthcare stocks to buy ac... Full story

Yahoo Finance • 12 months ago

Is Nuvation Bio Inc. (NUVB) Hedge Funds’ Favorite Penny Stock?

We recently published a list of 10 Most Promising Penny Stocks According to Hedge Funds. In this article, we are going to take a look at where Nuvation Bio Inc. (NYSE:NUVB) stands against other most promising penny stocks. Value in Small-... Full story

Yahoo Finance • last year

Innovent Announces Taletrectinib(ROS1 Inhibitor)Updated Data from Pivotal Phase 2 TRUST-I Study of are Published in the JCO and Orally Presentedat 2024 ASCO Annual Meeting

SAN FRANCISCO and SUZHOU, China, June 2, 2024 /PRNewswire/ -- Innovent Biologics, Inc. ("Innovent") (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercializes high-quality medicines for the treatm... Full story

Yahoo Finance • 2 years ago

16 Best Penny Stocks To Buy For 2024

In this article, we will take a detailed look at the16 Best Penny Stocks To Buy For 2024. For a quick overview of such stocks, read our article 5 Best Penny Stocks To Buy For 2024. The stock market’s optimism wave recently saw a break aft... Full story

Yahoo Finance • 2 years ago

Nuvation Bio Announces Departure of Chief Financial Officer

NEW YORK, November 13, 2023--(BUSINESS WIRE)--Nuvation Bio Inc. (NYSE: NUVB) (the "Company") announced today that Jennifer Fox will be stepping down from her role as Chief Financial Officer to pursue a new opportunity. Ms. Fox has advised... Full story

Yahoo Finance • 3 years ago

12 Best Biotech Stocks To Buy Under $20

In this piece, we will take a look at the 12 best biotechnology stocks to buy under $20. For more stocks, head on over to 5 Best Biotech Stocks To Buy Under $20. The biotechnology industry is one of the hottest sectors right now, particul... Full story

Yahoo Finance • 3 years ago

ProKidney Strengthens Board of Directors with Appointments of Dr. John M. Maraganore and Jennifer Fox

Maraganore brings more than 35 years of scientific, research and development, capital markets and managerial leadership expertise to ProKidney Fox joins Board with more than 25 years of healthcare investment banking, finance and capital m... Full story

Yahoo Finance • 3 years ago

Nuvation Bio, Inc. Investors: Company Investigated by the Portnoy Law Firm

Investors can contact the law firm at no cost to learn more about recovering their losses ​LOS ANGELES, July 05, 2022 (GLOBE NEWSWIRE) -- The Portnoy Law Firm advises Nuvation Bio Inc. (“Nuvation” or “the Company”) (NYSE: NUVB) investor... Full story

Yahoo Finance • 3 years ago

Nuvation Bio Announces FDA Partial Clinical Hold for Phase 1 Study of NUV-422 in Solid Tumors

NEW YORK, June 27, 2022--(BUSINESS WIRE)--Nuvation Bio Inc. (NYSE: NUVB), a biopharmaceutical company tackling some of the greatest unmet needs in oncology by developing differentiated and novel therapeutic candidates, today announced the... Full story